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Global identification of hnRNP A1 binding
sites for SSO-based splicing modulation
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and Brage S. Andresen1*
Abstract
Background: Many pathogenic genetic variants have been shown to disrupt mRNA splicing. Besides splice
mutations in the well-conserved splice sites, mutations in splicing regulatory elements (SREs) may deregulate
splicing and cause disease. A promising therapeutic approach is to compensate for this deregulation by blocking
other SREs with splice-switching oligonucleotides (SSOs). However, the location and sequence of most SREs are not
well known.
Results: Here, we used individual-nucleotide resolution crosslinking immunoprecipitation (iCLIP) to establish an in
vivo binding map for the key splicing regulatory factor hnRNP A1 and to generate an hnRNP A1 consensus binding
motif. We find that hnRNP A1 binding in proximal introns may be important for repressing exons. We show that
inclusion of the alternative cassette exon 3 in SKA2 can be significantly increased by SSO-based treatment which blocks
an iCLIP-identified hnRNP A1 binding site immediately downstream of the 5’ splice site. Because pseudoexons are well
suited as models for constitutive exons which have been inactivated by pathogenic mutations in SREs, we used a
pseudoexon in MTRR as a model and showed that an iCLIP-identified hnRNP A1 binding site downstream of the 5′
splice site can be blocked by SSOs to activate the exon.
Conclusions: The hnRNP A1 binding map can be used to identify potential targets for SSO-based therapy. Moreover,
together with the hnRNP A1 consensus binding motif, the binding map may be used to predict whether
disease-associated mutations and SNPs affect hnRNP A1 binding and eventually mRNA splicing.
Keywords: hnRNP A1, iCLIP, Splicing splice-switching oligonucleotides (SSOs), Pseudoexons, Alternative splicing,
Splicing silencer, Cross-linking immunoprecipitation (CLIP), RNA-seq, Surface plasmon resonance imaging (SPRi)
Background
Splicing of pre-mRNA is a key step in gene expression,
and alternative splicing, the production of multiple
mRNA isoforms from one gene, is a key mechanism to
expand the diversity of the human proteome. Stringent
regulation of splicing is crucial, since missplicing may
lead to the production of nonfunctional or malfunctional
mRNA isoforms. Splicing regulatory proteins regulate
splicing by binding to cis-acting splicing regulatory
elements (SREs). A fine balance between negative and
positive SREs determines the splicing fate of exons. Up
to one third of all disease-causing mutations may disrupt
pre-mRNA splicing [1, 2]. Mutations that affect pre-
mRNA splicing may directly or indirectly affect the rec-
ognition of the splice sites or the SREs. Alternatively,
mutations may create or disrupt SREs and in this way
disturb the complex regulatory network of splicing.
A well-studied example of a disease caused by dis-
ruption of an SRE is spinal muscular atrophy (SMA).
Patients with SMA lack a functional SMN1 gene and de-
pend on the SMN2 gene to survive. SMN2 is highly
homologous to SMN1, but a single nucleotide difference
in SMN2 exon 7 (c.840C > T) simultaneously disrupts a
splicing enhancer and introduces a splicing silencer,
which binds heterogeneous nuclear ribonucleoprotein
A1 (hnRNP A1) [3–7]. Hence, SMN2 has a high degree
of exon 7 skipping, which results in a nonfunctional pro-
tein. In patients with MCAD deficiency a mutation in
exon 5 (c.362C > T) disrupts a splicing enhancer and
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induces exon skipping. Interestingly, a silent polymorph-
ism in a flanking hnRNP A1-binding splicing silencer
can protect against exon 5 skipping [8].
A promising approach to treat diseases caused by ab-
errant splicing is the use of antisense oligonucleotide-
mediated splicing modulation [9, 10]. One way to do this
is to block SREs by complementary antisense oligonucle-
otides (also called splice-switching oligonucleotides,
SSOs) to make them inaccessible to splicing regulatory
proteins and thereby redirect splicing. One of the most
promising SSO-based therapies is targeting of the
hnRNP A1-binding splicing silencer N1 in SMN2 intron
7 to correct SMN2 splicing [11–14]. However, identifica-
tion of SREs which are suitable for this type of therapy is
not easy. Mutations that disrupt or create new SREs are
difficult to identify, since the binding sites for most spli-
cing regulatory proteins have mainly been characterized
by in vitro studies. Thus, there is limited knowledge of
the in vivo binding sites of splicing regulatory proteins;
moreover, splicing regulatory proteins may compete and
cooperate for binding in an unpredictable manner [15].
To identify in vivo binding sites, a number of RNA bind-
ing proteins have been subjected to crosslinking and im-
munoprecipitation (CLIP) analysis [16–24].
Here, we performed individual-nucleotide resolution
crosslinking immunoprecipitation (iCLIP) analysis of the
multifunctional RNA binding protein hnRNP A1. hnRNP
A1 is involved in many RNA processing events including
both constitutive and alternative splicing [25, 26]. Trad-
itionally, hnRNP A1 has been considered a splicing repres-
sor, though it may in some cases also stimulate splicing.
hnRNP A1 may repress splicing by antagonizing the func-
tion of positive splicing factors such as the SR proteins
[27–29]; alternatively, hnRNP A1 may sterically block
binding of SR proteins or members of the spliceosome to
prevent splice site recognition [30]. Furthermore, hnRNP
A1 proteins are able to multimerize after initial binding to
a high-affinity site and spread across an exon to inhibit its
inclusion [31]. Protein-protein interactions between
different hnRNP A1 molecules may also promote either
exon inclusion by looping out introns to reduce intron
size and stimulate splice site pairing, or cause exon
skipping by looping out exons to inhibit splice site recog-
nition [32–34].
Diseases associated with deregulated expression of
hnRNP A1 include several cancers [35–38] and Alzheimer’s
disease [39]. In addition, a number of diseases are caused
by mutations or single nucleotide polymorphisms (SNPs)
which create or abolish hnRNP A1 binding SREs. For ex-
ample, a missense mutation in the ETFDH gene improves
an hnRNP A1-binding splicing silencer, thereby inducing
exon 2 skipping and degradation of the ETFDH protein in
patients with multiple acyl-CoA dehydrogenation defi-
ciency [40]. In the PAH gene, a synonymous mutation
creates an hnRNP A1-binding splicing silencer, thereby
causing aberrant splicing and phenylketonuria (PKU) [41].
Also, a SNP affecting an hnRNP A1-binding SRE plays a
potential role in cardiovascular disease risk by altering the
alternative splicing of HMGCR [42]. Furthermore, a syn-
onymous SNP in exon 11 of ACADM disrupts an hnRNP
A1-binding SRE, which improves exon inclusion and may
influence fatty acid oxidation capacity [43].
Despite the fact that hnRNP A1 is a well-studied splicing
regulatory factor, transcriptome-wide in vivo binding of
hnRNP A1 has previously only been carried out as part of
a study comparing binding of several hnRNP proteins. In
that study, crosslinking and immunoprecipitation followed
by high-throughput sequencing (HITS-CLIP) analysis was
performed in HEK293T cells [17]. In the present study, we
have examined the transcriptome-wide binding of hnRNP
A1 by a newer method, iCLIP coupled with high-
throughput sequencing [44] in a different cell type, namely
HeLa cells. Our main goal is to create a more comprehen-
sive catalogue of hnRNP A1 binding sites to enable identi-
fication of disease-associated binding sites. In this study,
we increase the number of CLIP-identified hnRNP A1
binding sites in the human transcriptome approximately
20 times. This dramatically increases the number of iden-
tified hnRNP A1-binding SREs, which can serve as targets
for SSO-based therapy. While some binding sites overlap
between the two studies, many seem to be cell type- or
method-specific. Furthermore, we hypothesize that, by
combining the hnRNP A1 binding map with the validated
hnRNP A1 binding motif, one will be able to better predict
the effect of sequence variations on splicing. We find that
hnRNP A1 binding in the proximal intron is important for
hnRNP A1-mediated splicing repression, and that target-
ing these binding sites with SSOs can improve exon inclu-
sion. This will be useful for correction of splicing of
constitutive exons which have been inactivated by muta-
tions in SREs or to shift between alternatively spliced
exons. We selected pseudoexons as a model of constitutive
exons, which have been inactivated by mutations that either
abolish a splicing enhancer or create a splicing silencer, and
show that blocking of downstream hnRNP A1 binding sites
improves exon inclusion. Furthermore, we show that we
can shift the alternative splicing of SKA2 exon 3 towards
more inclusion when blocking an identified hnRNP A1-
binding splicing silencer downstream of the 5′ splice site.
Thus, as a proof of concept, we show here that hnRNP
A1 binding sites identified by iCLIP immediately down-
stream of the 5′ splice site can be blocked by SSOs to
activate splicing of exons.
Results
Transcriptome-wide analysis of hnRNP A1 binding sites
To analyze the transcriptome-wide binding of hnRNP
A1 to protein-coding genes, we performed iCLIP [44] in
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HeLa cells with inducible expression of T7-tagged
hnRNP A1 (Additional file 1: Figure S1). The T7-tagged
hnRNP A1 was previously described [45], and was
demonstrated to behave similarly to endogenous hnRNP
A1 [46]. After filtering, removal of PCR duplicates, and
adaptor removal, a total of 5,115,079 reads uniquely
aligned to the genome (Additional file 2: Table S1). Due
to the nature of the iCLIP protocol, the protein binding
site is assumed to be at the 5′ end of the sequencing
read [18, 47]. In some cases crosslinking will induce de-
letions; thus, the protein binding site is assumed to be at
the deletion site [48–50]. We tested our dataset with the
iCLIPro analysis tool [51], which confirmed that our
iCLIP reads do cluster around the 5′ end of the
reads (Additional file 3: Figure S2). In total, we iden-
tified 40,670 hnRNP A1 binding peaks in 6864 genes
(Additional file 4). We searched for enriched motifs in
the hnRNP A1 binding peaks and, confirming the validity
of our iCLIP approach, the most highly enriched motif
has high similarity to the SELEX-based motif UAGGGA/
U [25] and to the previous HITS-CLIP generated motifs
[17] (Fig. 1a).
Fig. 1 hnRNP A1 iCLIP identified UAGG as the hnRNP A1 binding motif. a Consensus hnRNP A1 binding motifs were generated based on the
identified hnRNP A1 binding peaks. The most highly enriched motif and the frequency matrix are shown. b The distribution of hnRNP A1 iCLIP
crosslinking sites in different genomic regions (pie chart). hnRNP A1 iCLIP crosslinking sites are most prevalent in introns. However, when
accounting for the relative size of each genomic region, there is an enrichment of hnRNP A1 crosslinking sites in the 3′ UTR (bar chart). CDS coding
sequence. c The distribution of hnRNP A1 binding peaks across introns, including 100 bases of the adjacent exons. hnRNP A1 binds deep introns more
than proximal introns close to exons. Shaded region corresponds to the 95 % confidence interval. d The distribution of hnRNP A1 binding peaks across
exons including 100 bp of the adjacent introns. Internal exons (green) defined as all exons except the first and last exon, and cassette exons (orange)
defined as alternative internal exons. hnRNP A1 binding peaks are highly enriched downstream of the 5′ splice site, more so for cassette exons than
internal exons in general. Shaded region corresponds to the 95 % confidence interval
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The hnRNP A1 crosslinking sites are predominantly
located in introns; however, when accounting for the
total length of the analyzed RNA regions, hnRNP A1
crosslinking is enriched within exonic regions, especially
in the 3′ UTR (Fig. 1b). Generally, hnRNP A1 binds uni-
formly across introns, though close to exons hnRNP A1
binding is reduced (Fig. 1c). hnRNP A1 may thus silence
introns by packaging pre-mRNA into hnRNP particles
and repress splicing of the vast number of pseudoexons
present in introns [52, 53], while exons are left free for
splice site recognition. Close to the 3′ splice site the
binding of hnRNP A1 increases (Fig. 1d); this may reflect
a low affinity towards the polypyrimidine tract region
immediately upstream of the 3′ splice site but high-
affinity binding near the 3′ splice site, which resembles
the hnRNP A1 binding motif [25]. We observe slightly
increased hnRNP A1 binding in the immediate flanking
intronic regions (±100 bases) of alternatively spliced
exons (cassette exons) when compared to this region in
all internal exons (Fig. 1d), suggesting that hnRNP A1 is
involved in regulation of alternative splicing by binding
in introns close to cassette exons. Furthermore, intronic
regions surrounding cassette exons are far more con-
served than those flanking constitutive exons, indicating
that these sequences are important for regulation of
alternative splicing [54]. A total of 240 hnRNP A1 bind-
ing peaks were identified inside or within 50 bp of cas-
sette exons (Additional file 4).
Blocking of the splice sites may be a major mechanism of
hnRNP A1-mediated exon repression
We speculated that the enrichment of hnRNP A1 bind-
ing near cassette exons would be further enriched near
exons actually regulated by hnRNP A1. Therefore, we
knocked down hnRNP A1 in HeLa cells and analyzed
the samples by RNA sequencing to identify splicing
events regulated by hnRNP A1 (Fig. 2a, b). Consistent
with the previous hnRNP A1 CLIP study [17], we find
that hnRNP A1 predominantly regulates cassette exons,
and in line with the established role of hnRNP A1 as a
splicing repressor, we observed that hnRNP A1 pre-
ferentially represses cassette exon inclusion (Fig. 2c,
Additional file 4); 18 exons were activated and 110 exons
were repressed by hnRNP A1. To identify if there is any
correlation between the effect of hnRNP A1 knockdown
and the location of hnRNP A1 binding sites, we mapped
the density of hnRNP A1 iCLIP crosslinking sites across
hnRNP A1-regulated exons and the upstream and down-
stream exons (Fig. 2d). The density of hnRNP A1 cross-
linking sites across the repressed exons is higher than
across activated exons, especially in the proximal
introns. This further supports the idea that binding of
hnRNP A1 in introns close to splice sites represses exon
inclusion by, for instance, steric blocking of the splice
sites. Inside exons, hnRNP A1 may repress exon inclu-
sion by antagonizing the binding and function of positive
splicing regulatory proteins such as the SR proteins. The
sequence composition might affect the ability of hnRNP
A1 to polymerize along the exon as previous models of
hnRNP A1 repression suggest, and to investigate this we
examined the GC content in the affected exons and in
100-bp regions surrounding the exons (Additional file 5:
Figure S3). We found that the GC content is sig-
nificantly decreased in repressed exons relative to un-
affected exons while there was no significant difference
in the activated exons, indicating that there are more
hnRNP A1 binding motifs in repressed than activated
exons, consistent with a model in which hnRNP A1 acti-
vates exon splicing indirectly and not by binding directly
to sites near the exon.
Since cassette exons generally have weaker splice sites
than constitutive exons, hnRNP A1 may generally inter-
fere more with the recognition of the splice site of cas-
sette exons, since U1 snRNP and U2AF are less capable
of competing with the binding of hnRNP A1 at these
splice sites. We hypothesized that exons regulated by
hnRNP A1 would have even weaker splice sites. We
therefore estimated splice site strength with the Maxent
scoring algorithm [55], and found that among the re-
pressed exons the 5′ splice sites were weaker than in un-
affected exons (Wilcoxon rank sum test, p = 0.02278).
The activated exons also showed a trend towards lower
score, although not to a statistically significant extent
(Wilcoxon rank sum test, p = 0.05643) (Fig. 2e). There
was no significant change in the strength of the 3′ splice
site, indicating that the 5′ splice site may be a primary
target of regulation by hnRNP A1.
iCLIP identifies hnRNP A1 binding sites in
disease-associated genes
We wanted to use our hnRNP A1 iCLIP binding map to
identify binding sites in disease genes. A number of the
hnRNP A1-regulated cassette exons identified by RNA
sequencing were found in disease-associated genes
(Additional file 2: Table S2). Furthermore, we identify
hnRNP A1 binding sites in a number of known disease-
associated genes (Additional file 4). Splicing of the mu-
tually exclusive PKM exons 9 and 10 determines the
metabolic switch towards lactate production and the
Warburg effect in cancer cells [56–60]. We observed in-
creased inclusion of PKM exon 9 and increased skipping
of exon 10 after hnRNP A1 knockdown, and a large
number of hnRNP A1 reads at the previously identified
hnRNP A1 binding sites in PKM exon 9 and intron 9,
consistent with the proposed regulatory role of hnRNP A1
in PKM alternative splicing (Additional file 6: Figure S4A).
Interestingly, we identify an hnRNP A1 binding site in
exon 10 that overlaps a previously reported splicing
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Fig. 2 hnRNP A1 binds downstream of the 5′ splice site of repressed exons. a Validation of hnRNP A1 knockdown by western blotting. b RT-PCR
validation of hnRNP A1-regulated splicing events identified by RNA sequencing of hnRNP A1-depleted HeLa cells. Representative of two replicates.
PSI percent spliced in; semi-quantification of bands on agarose gels by ImageJ. c Types of alternative splicing events regulated by hnRNP A1
identified by hnRNP A1 knockdown and RNA sequencing. Most splicing events regulated by hnRNP A1 are splicing of cassette exons. Most of
the regulated cassette exons are repressed by hnRNP A1. d Distribution of hnRNP A1 iCLIP tags in cassette exons activated (green) or repressed
(orange) by hnRNP A1 and the upstream and downstream exons. The analysis was based on 18 activated exons and 110 repressed exons found
by RNA sequencing of hnRNP A1-depleted HeLa cells (n = 3). The hnRNP A1 crosslinking site density is higher across cassette exons repressed by
hnRNP A1 than cassette exons activated by hnRNP A1, suggesting that hnRNP A1 exon repression is a direct mechanism, while hnRNP A1 exon
activation is an indirect mechanism. There is no difference between the distribution of hnRNP A1 iCLIP tags in upstream and downstream exons
of hnRNP A1-activated and hnRNP A1-repressed exons. The region immediately downstream of the 5′ splice site seems to be important for
hnRNP A1-mediated exon repression. The level of hnRNP A1 crosslinking sites in exons not affected by hnRNP A1 knockdown is shown in purple.
Shaded region reflects the 95 % confidence interval. e Maxent score for 3′ splice sites and the 5′ splice sites of hnRNP A1-activated, -repressed, or
neutral cassette exons. *p value < 0.05. Wilcoxon rank sum test, p = 0.02278. ns non-significant. Error bars are standard error of mean
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silencer. This silencer is normally masked by an adjacent
splicing enhancer, and only when it was inserted in a
different context did it function as a silencer [60].
The role of hnRNP A1 in regulating splicing of SMN2
exon 7 has been extensively studied. However, the high
similarity of SMN1 and SMN2 (more than 99 % identical
nucleotides) makes it impossible to uniquely map all the
reads in the two transcripts. In our iCLIP analysis, we
filtered away non-unique reads, so, initially, we obtained
only few reads mapping to SMN1 and SMN2. Thus, to
identify all reads in SMN1 and SMN2, we also examined
the non-unique reads. We identified hnRNP A1 cross-
linking sites overlapping all the functionally important
motifs previously demonstrated to regulate SMN2 exon
7 splicing by hnRNP A1 binding. (1) We identified the
hnRNP A1 binding peak in intron 7 position +100 in
SMN2, which is an SMN2-specific hnRNP A1 binding
site (Fig. 3a) [61]. (2) We identified one hnRNP A1
crosslinking site in SMN2 exon 7 (and not in SMN1) at
the silencer motif created by the SMN2-specific muta-
tion (Fig. 3b, ESS), supporting the idea that the SMN2
exon 7 mutation both disrupts an SRSF1 binding
splicing enhancer and creates an hnRNP A1-binding
splicing silencer [7, 62]. (3) We identified the hnRNP
A1-binding splicing silencer that overlaps the 3′ splice
site of both SMN1 and SMN2 exon 7 (Fig. 3b, ISS) [63].
Interestingly, we observe the hnRNP A1 crosslinking site
only in SMN2 consistent with our previously proposed
model, which suggests that binding of hnRNP A1 to this
splicing silencer is synergistic with binding of hnRNP A1
to the other splicing silencers in SMN2 that inhibit exon
7 inclusion. (4) The hnRNP A1 binding intronic silencer
N1 [12] is identical in SMN1 and SMN2 and conse-
quently it was not identified in the initial analysis, but
manual analysis did identify two hnRNP A1 crosslinking
sites at this well-known hnRNP A1-binding splicing si-
lencer (Additional file 6: Figure S4B). This exemplifies
that it is a general problem that most sequencing reads
from highly similar regions cannot be uniquely aligned.
Altogether, our results support that hnRNP A1 generally
binds more efficiently to the SMN2 transcript than to
the SMN1 transcript, and therefore splicing of SMN2
exon 7 is inhibited.
We suggest that our hnRNP A1 iCLIP binding map
can also be used to predict if pathogenic mutations will
affect hnRNP A1 binding. We find an enrichment of
hnRNP A1 iCLIP reads in the long exons (exon 11) of
BRCA1 and BRCA2 (Additional file 7: Figure S5A, B),
indicating that hnRNP A1 is particularly important for
the splicing of these exons. The hnRNP A1 binding
peaks in these exons co-localize with a number of un-
classified or pathogenic SNPs, and we found two SNPs
in both BRCA1 and BRCA2 which disrupt the identified
hnRNP A1 binding motif (Additional file 7: Figure S5C),
suggesting that these SNPs affect hnRNP A1 binding.
We performed RNA oligonucleotide-affinity chromatog-
raphy of HeLa nuclear extracts followed by western
blotting with hnRNP A1 specific antibody, and indeed
we observed that three of the SNPs (rs398122533,
rs80357105, and rs80357458) reduced hnRNP A1 bind-
ing and thus they could potentially affect splicing.
Blocking of iCLIP-identified hnRNP A1 binding sites
improves splicing of cassette exons
Since we observed that hnRNP A1 binding to sites close
to the splice sites may be important mechanisms of
hnRNP A1-regulated splicing repression, we hypothe-
sized that SSO-mediated blocking of these sites could be
used to activate exons. Since SSOs targeting introns
close to the 3′ splice site may interfere with the recogni-
tion of the polypyrimidine tract, it would likely be easier
to activate exons by blocking hnRNP A1 binding sites
close to the 5′ splice site. Furthermore, since we ob-
served a significant lower strength of the 5′ splice site in
hnRNP A1-regulated exons, but not in the strength of
the 3′ splice site, compared with unaffected exons
(Fig. 2), the 5′ splice site may be a primary target of
regulation by hnRNP A1. Thus modulation of 5′ splice
site strength by blocking a nearby hnRNP A1 binding
motif would have a greater effect on exon splicing. The
efficient correction of SMN2 exon 7 inclusion obtained
by SSO-mediated blocking of the hnRNP A1-binding
silencer N1 flanking the 5′ splice site in SMN2 supports
this hypothesis [14].
To identify potential alternative cassette exons, where
exon inclusion could be improved by SSO-mediated
blocking of hnRNP A1 binding sites, we examined the
distribution of hnRNP A1 iCLIP crosslinking sites in
cassette exons identified by hnRNP A1 knockdown. Two
iCLIP crosslinking sites were located 11 nucleotides
downstream of the 5′ splice site of the alternative exon
3 in the SKA2 gene, and this region covers five potential
hnRNP A1 binding sites containing the CAG/UAG tri-
nucleotide (Fig. 4). Furthermore, the inclusion of SKA2
exon 3 was higher in HeLa cells depleted of hnRNP A1
than in control cells (Fig. 4a). SKA2 is part of the SKA
complex which binds microtubules and is necessary for
correct cell division in human cells [64]. SKA2 expres-
sion is upregulated in lung cancer and involved in the
progression of the disease, but it is not known which of
the alternatively spliced SKA2 transcripts (with or with-
out exon 3) are, or if they are both, upregulated in lung
cancer [65]. To confirm binding of hnRNP A1 down-
stream of the 5′ splice site of SKA2 exon 3, we performed
RNA oligonucleotide-affinity chromatography of HeLa
nuclear extracts followed by western blotting (Fig. 4b and
Additional file 8: Figure S6A). We used RNA oligonucleo-
tides in which the important UAG/CAG trinucleotide is
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inactivated by a 2A > C mutation to UCG/CCG. Accord-
ing to our hnRNP A1 binding motif (Fig. 1a), this change
is expected to disrupt hnRNP A1 binding, and we have
previously demonstrated that the 2A > C mutation of the
UAG/CAG motif disrupts hnRNP A1 binding [8, 40, 63].
We identified hnRNP A1 motif-specific binding of hnRNP
A1 to the SKA2 exon 3 oligonucleotides and found that
hnRNP A1 binds in an additive way to the motifs present
in this region. Confirming the validity of our identified
hnRNP A1 binding motif, we find that mutating the
UUAGAUUU motif to UUAGGGAU, which resembles
our hnRNP A1 consensus binding motif, increases hnRNP
A1 binding. The binding of hnRNP A1 to the region
downstream of the exon 3 5′ splice site was also
Fig. 3 hnRNP A1 iCLIP reads in the SMN2 gene pinpoint well-known hnRNP A1 binding sites. hnRNP A1 iCLIP identifies well-known hnRNP A1
binding sites in SMN2 exon 7. The intronic splicing silencer (ISS) located at the 3′ splice site. The SMN2-specific exon splicing silencer (ESS) in exon
7, the N1 intronic silencer, and the +100 intronic silencer. a hnRNP A1 iCLIP identifies an hnRNP A1 binding site in SMN2 at the hnRNP A1-dependent
silencer in intron 7 + 100. The highly identical SMN1 and SMN2 genes differ at this position (framed: SMN1 + 100A, SMN2 + 100G); previous studies
showed the +100G is necessary for strong splicing silencer activity. The iCLIP crosslinking site, i.e., the protein binding site, is assumed to be at the
beginning of the sequencing reads (gray) when performing iCLIP. The hnRNP A1 binding peak is represented by a blue line. Only two hnRNP A1 reads
were identified in SMN1 at this location (not shown). Screenshot from IGV. b hnRNP A1 iCLIP reads in SMN2 at the hnRNP A1-dependent silencer at
the exon 7 3′ splice site (ISS) and at the hnRNP A1-dependent silencer generated by the C > T variation (framed) in SMN2 (ESS). No reads were found
in SMN1 at this position (not shown). To ensure that the higher number of hnRNP A1 reads in SMN2 than in SMN1 was not due to higher gene
expression, we performed SMN1 and SMN2-specific RT-qPCR (data not shown). This proved that the expression of SMN1 and SMN2 was similar in these
cells, and thus was likely not the reason for the higher number of hnRNP A1 reads in SMN2
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confirmed by surface plasmon resonance imaging (SPRi)
(Additional file 8: Figure S6B). To further examine the
mechanism of hnRNP A1-mediated repression of SKA2
exon 3, we constructed SKA2 minigenes containing exon
2, exon 3, and part of exon 4 and shortened intervening in-
trons (see Methods section) (Additional file 9: Figure S7).
Unfortunately, we had to dramatically reduce the length of
introns 2 and 3 (intron 2 was reduced from 11,785 nt to
1305 nt and intron 3 was reduced from 6973 nt to
1200 nt) to allow construction of the minigene. This re-
sulted in very efficient, nearly complete, exon 3 inclusion
in the minigene context, probably due to the reduction of
intron sizes, which is known to improve exon inclusion.
Although, exon 3 skipping from the minigene was minimal
compared to the endogenous SKA2 gene, we did observe
that disruption of the hnRNP A1 binding motifs by mutat-
ing the important UAG/CAG to UCG/CCG results in
complete exon inclusion. This is consistent with the
Fig. 4 SSOs targeting an hnRNP A1 binding site downstream of SKA2 exon 3 improve exon inclusion. a RT-PCR of SKA2 exon 3 splicing in HeLa
cells with (KD) or without (Ctrl) hnRNP A1 knockdown. hnRNP A1 knockdown increases SKA2 exon 3 inclusion. PSI percent spliced in; semi-quantification
of bands on agarose gels by ImageJ. b Western blot of proteins purified by RNA-affinity chromatography of biotin-conjugated RNA oligonucleotides
covering the three putative hnRNP A1 binding sites near the 5′ splice site of SKA2 exon 3. hnRNP A1 binding motifs are underscored, and mutations
disrupting the hnRNP A1 binding motifs are shown in red. Introduction of the mutations reduces hnRNP A1 binding, while modifying one of the hnRNP
A1 motifs to match our generated consensus binding motif (green) improves hnRNP A1 binding. The score of the putative hnRNP A1 motifs were
calculated based on our generated scoring matrix (Additional file 1: Figure S1). Representative of two experiments. c hnRNP A1 iCLIP reads at the 5′
splice site of SKA2 exon 3. hnRNP A1 may bind downstream of the 5′ splice site to repress 5′ splice site recognition. The target site for the SKA2 exon 3
SSO is shown in green. The gene is on the antisense strand. Screenshot from IGV. d Transfection of SSOs targeting the hnRNP A1 binding
site downstream of the 5′ splice site in SKA2 exon 3 into HeLa, HEK293, or A549 cells improves exon inclusion. The intensity of the bands
was semi-quantified using ImageJ. PSI percent spliced in
Bruun et al. BMC Biology  (2016) 14:54 Page 8 of 19
proposed model suggesting that hnRNP A1 binds near the
5′ splice site of SKA2 exon 3 and represses exon inclusion.
To test our hypothesis that exons can be activated by
blocking hnRNP A1 binding sites adjacent to the 5′
splice site, we designed an SSO covering three hnRNP
A1 binding sites near the 5′ splice site of SKA2 exon 3.
Transfection of this SSO into HeLa cells, HEK293 cells,
and the lung cancer cell line A549 significantly improves
SKA2 exon 3 inclusion endogenously (Fig. 4c, d) and in
the minigene (Additional file 9: Figure S7C). Further-
more, we show that a dose-response curve exists be-
tween the dose of SSO and the amount of SKA2 exon 3
inclusion in HeLa cells (Additional file 9: Figure S7D).
Altogether, this supports the idea that blocking of iCLIP-
identified hnRNP A1 binding sites downstream of the 5′
splice site is a feasible way to improve splicing of alter-
native exons.
SSO-mediated blocking of hnRNP A1 binding sites
improves inclusion of inactivated exons
To further examine the potential of blocking hnRNP A1
binding sites near the 5′ splice sites of weak or inactivated
exons, we used pseudoexons as a model of constitutive
exons inactivated by mutations in SREs [3–8, 40, 41]. A
group of pseudoexons in the PCCA, GLA, FGB, CFTR,
ATM, MTRR, and COL4A5 genes are activated by disease-
causing point mutations, which either disrupt a splicing
silencer or create a splicing enhancer [53, 66–72]. We
examined the presence of hnRNP A1 iCLIP binding peaks
between the 5′ splice site and 100 bp downstream in these
seven pseudoexons. We identified an hnRNP A1 binding
peak downstream of the MTRR pseudoexon (approxi-
mately 11 bases from the 5′ splice site in intron 6) (Fig. 5a)
The region downstream of the 5′ splice site of the MTRR
pseudoexon contains three potential hnRNP A1 binding
sites, and when introducing the 2A > C mutation at all
these sites (MUT A), the binding of hnRNP A1 was sig-
nificantly reduced (Fig. 5b). When analyzing oligonucleo-
tides containing mutations at only one or two of these
sites (MUT B, MUT C, and MUT D), we observed hnRNP
A1 binding only when the motif closest to the 5′ splice
site was intact. This was confirmed by SPRi analysis. We
observed that hnRNP A1 bound with approximately nine
times higher affinity to the wild-typeMTRR sequence than
to the MUT A sequence (Additional file 10: Figure S8).
However, when leaving only the proximal hnRNP A1
binding site intact (MUT B), the affinity for hnRNP A1
was similar to the wild-type sequence. We could not
detect binding of hnRNP A1 to MUT C and MUT D
oligonucleotides using SPRi; thus, in contrast to the
hnRNP A1 binding sites near SKA2 exon 3, the binding
sites in MTRR were not additive, as the proximal hnRNP
A1 binding site seems to be required for hnRNP A1 bind-
ing. This site could thus function as the nucleating site of
hnRNP A1 binding from which polymerization to lower
affinity sites can be initiated. Confirming the importance
of hnRNP A1 in MTRR pseudoexon repression, hnRNP
A1 knockdown in HeLa cells increased MTRR pseu-
doexon inclusion approximately 5 times compared to con-
trol cells (Fig. 5c).
We also identified an hnRNP A1 binding peak approxi-
mately 70 bases from the 5′ splice site of the COL4A5
pseudoexon in intron 6. We examined the binding of
hnRNP A1 to sequences covering the putative hnRNP A1
binding site near the COL4A5 pseudoexon. The introduc-
tion of the 2A >C mutation in the COL4A5 oligonucleo-
tide reduced hnRNP A1 binding as shown by both RNA
oligonucleotide-affinity chromatography and SPRi analysis
(Additional file 11: Figure S9). The COL4A5 pseudoexon
inclusion was, however, not improved after hnRNP A1
knockdown in HeLa cells (Additional file 12: Figure S10A).
To examine if the inclusion of the MTRR and COL4A5
pseudoexons could be improved by blocking the hnRNP
A1 binding sites downstream of the 5′ splice site, we de-
signed SSOs blocking the putative hnRNP A1 binding
sites and transfected HeLa and HEK293 cells (Fig. 5d,
Additional file 12: Figure S10B and S10C). Transfection
of the SSOs dramatically improved inclusion of the
endogenous MTRR pseudoexon. This is a direct effect of
the SSO treatment, as we demonstrate a dose-response
relationship between SSO concentration and MTRR
pseudoexon inclusion (Additional file 13: Figure S11).
This suggests that binding of hnRNP A1 downstream of
the MTRR pseudoexon directly represses pseudoexon
inclusion, and that this splicing silencer is a major deter-
minant of pseudoexon repression, which can be antago-
nized by SSO treatment to enable considerable levels of
inclusion. Consistent with the results of siRNA-mediated
knockdown of hnRNP A1, SSO-mediated blocking of the
COL4A5 hnRNP A1 binding site did not improve COL4A5
pseudoexon inclusion, indicating that the hnRNP A1 bind-
ing site near the COL4A5 pseudoexon is not a major
determinant for COL4A5 pseudoexon repression.
Taken together, our data corroborate our hypothesis
that iCLIP can be used to pinpoint important regulatory
hnRNP A1 binding sites close to the 5′ splice site, and
that splicing of alternatively spliced cassette exons or
constitutive exons weakened from point mutations in
SREs can be corrected by SSO-mediated blocking of the
identified hnRNP A1 binding sites.
Discussion
Approximately 10–15 % of all disease-causing mutations
are located in splice sites, and an estimated 25 % of ex-
onic disease-causing mutations also affect pre-mRNA
splicing [73]. As an increasing number of patients will
be subject to gene sequencing for diagnostic and thera-
peutic purposes, there is a growing demand to be able to
Bruun et al. BMC Biology  (2016) 14:54 Page 9 of 19
Fig. 5 SSOs targeting hnRNP A1 binding sites downstream of the MTRR pseudoexon improve pseudoexon inclusion. a Model of the hnRNP
A1-mediated repression of the MTRR pseudoexon based on the hnRNP A1 iCLIP reads. The significant hnRNP A1 binding peak downstream of the
5′ splice site is indicated. hnRNP A1 may bind downstream of the 5′ splice site to repress splice site recognition by U1 snRNP. The target site for
the MTRR SSO (green) covers three hnRNP A1 binding motifs. b Western blot with hnRNP A1 or as control TDP43 antibody of proteins purified by
RNA-affinity chromatography of biotin-conjugated RNA oligonucleotides covering the downstream region of the MTRR 5′ splice site. Disruption of
the hnRNP A1 binding motifs reduces hnRNP A1 binding. The motifs are scored using our generated scoring matrix (Additional file 1: Figure S1).
The proximal hnRNP A1 motif is required for hnRNP A1 binding. hnRNP A1 binding motifs are underscored, and mutations disrupting the motifs
are red. Representative of three experiments. c RT-qPCR analysis of the inclusion of the endogenous MTRR pseudoexon in control and hnRNP
A1 knockdown HeLa cells. MTRR pseudoexon inclusion increases after hnRNP A1 knockdown. d RT-PCR of SSO-treated HeLa or Hek293 cells.
SSO-mediated blocking of the hnRNP A1 binding sites near the MTRR pseudoexon improves endogenous MTRR pseudoexon inclusion. SSO transfections
were done in duplicate and gel bands were semi-quantified using ImageJ. PSI percent spliced in
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predict the consequences of genetic variation. We used
iCLIP to identify the transcriptome-wide binding sites of
hnRNP A1 in HeLa cells and identified more than
40,000 hnRNP A1 binding sites across the transcriptome.
iCLIP thus provides a map of occupied in vivo binding
sites, and using the identified hnRNP A1 binding sites,
we derived an hnRNP A1 consensus binding motif
(Fig. 1a). Together, this enables us to evaluate the effect of
genetic variation on hnRNP A1 binding and, as we show
here, identify target sites for SSOs to redirect splicing.
The hnRNP A1 binding motif that we generate resem-
bles the in vitro SELEX-based motif and the motif re-
ported from the previous HITS-CLIP study [17]. Also
previously identified functional hnRNP A1 binding sites
are consistent with our consensus motif [57, 74–76],
including the UAGGGA motif created by a c.158A > G
mutation in the ETFDH gene which creates an hnRNP
A1 binding site [40]. When we analyzed the generated
ETFDH hnRNP A1 binding motif, UAGGGA, along with
the wild-type sequence UAAGGA by SPRi using recom-
binant hnRNP A1, we found the mutant motif to bind
hnRNP A1 with approximately six times higher affinity
than the wild-type motif, confirming that UAGG is a
strong hnRNP A1 motif (Additional file 14: Figure S12).
Overall, this hnRNP A1 iCLIP analysis in HeLa cells is
consistent with the previous hnRNP A1 HITS-CLIP study
using HEK293T cells [17] (Additional file 2: Tables S3
and S4; Additional file 4). We find similar distributions of
hnRNP A1 binding sites across the transcriptome, with
the 3′ UTR being the most enriched region. This probably
reflects some of the non-splicing functions of hnRNP A1.
Furthermore, after hnRNP A1 knockdown in both HeLa
and HEK293T cells, cassette exons are the most deregu-
lated splicing event. In particular, hnRNP A1 mainly re-
presses cassette exon inclusion. Nineteen (15 %) of the
cassette exons we identify in this study to be regulated by
hnRNP A1 were also detected in HEK293T cells, including
KIF23 and LAS1L (Additional file 4). We identified ap-
proximately 20 times more binding peaks than the previ-
ous HITS-CLIP study (Additional file 2: Table S3). This
may be explained by the higher sensitivity of our iCLIP
approach compared to the HITS-CLIP-based approach
and the higher number of aligned reads in our study. For
comparison we analyzed the HITS-CLIP hnRNP A1
dataset [17] in a similar way as we analyzed our own data.
This resulted in identification of 1432 binding peaks,
which is still less than 20 times the number we obtained
(Additional file 2: Table S3). Of these 1432 binding peaks,
328 (23 %) overlapped with our hnRNP A1 iCLIP binding
peaks. Altogether, this suggests that in vivo hnRNP A1
binding sites are cell-type specific, and that CLIP analysis
in different cell lines will significantly increase the number
of known hnRNP A1 binding sites in the transcriptome.
Thus, there may still be important disease-associated
hnRNP A1 binding sites in genes which we do not detect
in HeLa cells because of, e.g., low expression levels. How-
ever, we believe that this iCLIP analysis can be used as a
guide to identify potential hnRNP A1 binding sites, espe-
cially if one includes not only the significant iCLIP binding
peaks but also individual reads and clusters of reads.
The binding profile of hnRNP A1 is consistent with
several of the reported hnRNP A1 splicing mechanisms.
hnRNP A1 preferentially binds introns, likely reflecting
the inhibitory role of hnRNP A1 in splice site re-
cognition [31, 33, 77] (Fig. 1b, c). hnRNP A1 may thus
be important in suppressing the usage of the numerous
cryptic splice sites in introns [78]. Interactions between
intronic hnRNP A1 proteins may also promote exon
skipping by looping out alternative exons [32, 33]. Alter-
natively, interactions with other hnRNP A/B proteins
bound in the same intron will loop out or condense the
intron to improve exon recognition [34]. In hnRNP A1-
mediated repressed exons, we observe a high density of
hnRNP A1 crosslinking sites in the immediate flanking in-
trons compared to both activated exons and unaffected
exons (Fig. 2d). This suggests that these are important re-
gions for hnRNP A1-mediated splicing repression and that
hnRNP A1 represses exons directly by sterically blocking
U1 snRNP or U2AF recognition of the splice sites. We ob-
serve weaker 5′ splice sites in hnRNP A1-repressed cas-
sette exons than in unaffected exons, indicating that the
5′ splice site is the target for hnRNP A1-mediated exon
repression. Generally, the hnRNP A1-repressed exons
have a high density of hnRNP A1 crosslinking sites, indi-
cating that hnRNP A1 also represses exons by other
mechanisms, for example, by antagonizing the binding
and function of SR proteins. In general, hnRNP A1-
activated exons and their proximal introns have fewer
hnRNP A1 crosslinking sites than repressed exons, sug-
gesting that hnRNP A1 activates exons in an indirect way.
Furthermore, hnRNP A1 may also regulate gene expres-
sion and splicing indirectly. hnRNP A1 iCLIP binding
peaks were abundant in the pre-mRNAs encoding hnRNP
proteins, in particular in the 3′ UTR region (Additional
file 15: Figure S13). We identified hnRNP A1 binding
peaks in the 3′ UTR of HNRNP A2/B1, where hnRNP A1
binding has been shown to induce alternative splicing,
resulting in an mRNA transcript downregulated by non-
sense mediated decay (NMD) [17, 29]. These results are
also consistent with the findings from Huelga et al. A large
number of iCLIP crosslinking sites were also present in
hnRNP A1’s own pre-mRNA. hnRNP A1 exists as two iso-
forms depending on the inclusion of exon 7B. The longer
isoform binds more strongly to RNA, but with less
capability to regulate alternative splicing [79]. Different
elements in the intronic region surrounding exon 7B are
implicated in HNRNP A1 alternative splicing [33, 80, 81],
and we identified hnRNP A1 binding peaks at the hnRNP
Bruun et al. BMC Biology  (2016) 14:54 Page 11 of 19
A1-dependent CE1 and CE4 splicing regulatory elements
near exon 7B. Besides the hnRNP proteins, we find
hnRNP A1 binding peaks in a large number of other
splicing regulatory proteins, including many of the SR
proteins such as SRSF1 and SRSF2 (Additional file 4). We
identified 1141 genes (false discovery rate [FDR] <0.1)
with altered expression after hnRNP A1 knockdown in
HeLa cells (Additional file 4). An interesting observation
was the finding that the oncogenic transcription fac-
tor c-Myc was upregulated in response to hnRNP A1
knockdown. This is consistent with the proposed regula-
tory feedback loop where c-Myc upregulates hnRNP A1
transcription and hnRNP A1 downregulates c-Myc by
blocking the biogenesis of let-7a, which in turn downregu-
lates c-Myc [82].
We believe our hnRNP A1 binding map can be used
to identify important hnRNP A1 binding sites in disease-
associated genes. We identify well-known hnRNP A1
binding sites in SMN1/2 and PKM. However, some of
these well-documented hnRNP A1 binding sites were
covered by only a few reads. Other well-documented
hnRNP A1 binding sites were also represented by rela-
tively few reads, such as the previously reported hnRNP
A1 binding site (CAGGGG at c.350–c.355) in an exonic
splicing silencer in ACADM exon 5 [8]. Although this
splicing silencer is functionally important, the fact that it
is positioned close to a splicing enhancer may prevent
strong hnRNP A1 binding and thus limit detection by
CLIP methods. It is well known that splicing regulatory
proteins compete for binding at closely spaced silencers
and enhancers in a finely tuned balance; thus, the pro-
teins that bind at the splicing enhancer may sterically
block the adjacent splicing silencer. If a mutation dis-
rupts the splicing enhancer, this will allow increased
hnRNP A1 binding to the silencer and inhibit exon
inclusion, as observed for ACADM exon 5 [8]. Thus, in
regions with low read coverage, functional hnRNP A1
silencers may be represented by only a few reads,
because hnRNP A1 competes with other proteins for
binding in vivo. This may also be the reason why we
only identify hnRNP A1 crosslinking at the 3′ splice site
of SMN2 and not of SMN1, where it is antagonized by
SRSF1 binding at the adjacent SMN1-specific enhancer.
As an increasing number of pathogenic genetic vari-
ants are found to affect mRNA splicing, the ability to
reverse or compensate splicing will be of great value.
Employing SSOs which block access to hnRNP A1-
binding splicing silencers may be a way to shift between
alternatively spliced isoforms or relieve the repression of
a splicing-incompetent exon, as illustrated by the very
successful upregulation of SMN2 exon 7 inclusion by
SSO-mediated blocking of the hnRNP A1-binding spli-
cing silencer N1 [14]. Since SSOs targeting introns flank-
ing the 3′ splice site may interfere with the recognition
of the polypyrimidine tract, we expect that SSO-
mediated blocking of the hnRNP A1 binding sites close
to the 5′ splice site will be a much more feasible way of
activating exons. Here, we demonstrated that inclusion
of the alternative cassette exon 3 in SKA2 can be signifi-
cantly increased by SSO-mediated blocking of an iCLIP-
identified hnRNP A1 binding site downstream of the 5′
splice site (Fig. 4d). However, we do not know whether
this approach can be exploited therapeutically in the
future, as the functional importance of the alternative
splicing of SKA2 exon 3 is still unknown.
Cassette exons are vulnerable exons with generally
weak splice sites; therefore, they may be rather easily
manipulated. Ideally, we would also like to use this ap-
proach to improve inclusion of constitutive exons which
are skipped due to pathogenic mutations in SREs. How-
ever, since constitutive exons are normally included in
the mRNA transcript, we cannot test the usability of
splicing-improving SSOs on these exons. A group of
pseudoexons which contain functional splice sites are
inactivated by mutations in SREs, and thus these pseu-
doexons functionally resemble constitutive exons inacti-
vated by mutations in SREs. We identified hnRNP A1
binding sites located close to the 5′ splice site of a pseu-
doexon of this type in MTRR (Fig. 5a), and we show that
SSO-mediated blocking of these hnRNP A1 binding sites
dramatically increases exon inclusion (Fig. 5d). This pro-
vides a clear proof of the principle that iCLIP-identified
hnRNP A1 binding sites can be targeted by SSOs to im-
prove inclusion of inactivated exons. Blocking of the
hnRNP A1 binding site downstream of the COL4A5
pseudoexon did not, however, increase exon inclusion
(Additional file 12: Figure S10C). The hnRNP A1 bind-
ing site downstream of the COL4A5 pseudoexon is
70 bp from the 5′ splice site, whereas the hnRNP A1
binding sites downstream of SKA2 exon 3 and the
MTRR pseudoexon are located only 11 bp from the 5′
splice sites. This could indicate that SSO-mediated
blocking of hnRNP A1 binding sites only improves exon
inclusion when the target site is close to the 5′ splice
site. Also the hnRNP A1-binding N1 splicing silencer in
SMN2 exon 7 is located only 11 bp from the 5′ splice
site, supporting the idea that hnRNP A1 binding sites
located immediately (10–40 bp) downstream of 5′ splice
sites are good targets for this SSO-based approach.
Conclusion
We show here that our hnRNP A1 binding map can be
used to identify functional hnRNP A1 binding sites, and
that hnRNP A1 binding sites immediately downstream
of the 5′ splice site can be blocked by SSOs to increase
exon inclusion. This may be a useful therapeutic
approach to compensate for the missplicing caused
by pathogenic genetic variants in splicing regulatory
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elements. Furthermore, in combination with our hnRNP
A1 binding map, our generated hnRNP A1 binding motif
will enable identification of hnRNP A1 binding sites which
have been created or disrupted by genetic variants or
mutations to cause aberrant splicing and disease.
Methods
iCLIP analysis
iCLIP was performed as described [44] with three
biological replicates. Briefly, HeLa cells with stable
inducible expression of T7-tagged hnRNP A1 [45] were
cultured in RPMI 1640 with L-glutamine (Lonza) sup-
plemented with streptomycin, penicillin, and glutamine.
Cells were seeded in 10-cm dishes and induced with
1 μg/ml doxycycline (Sigma-Aldrich) for 48 h before UV
crosslinking. At the time of crosslinking, cells were ap-
proximately 90 % confluent. After cell lysis, samples
were sonicated and RNase treated with RNase Cocktail™
Enzyme Mix (Life Technologies), a mixture of RNaseA
and RNaseT1 diluted 1:10, 1:200, and 1:2000. T7-hnRNP
A1 was immunopurified with Dynabeads Protein G (Life
Technologies) coupled to anti-T7-antibody (69522-4,
Merck Millipore). RNA-protein complexes were sepa-
rated by size by SDS-PAGE and transferred to a nitrocel-
lulose membrane from which RNA-protein complexes of
an appropriate size (>20 kDa above protein size) were
cut out. Subsequently, the protein was digested by Pro-
teinase K (Fisher Scientific). cDNA was synthesized with
Superscript II Reverse Transcriptase (Life Technologies)
and purified on a 5 % TBE-Urea gel (Bio-Rad). The
cDNA was circularized using CircLigase II ssDNA
Ligase (Epicentre), relinearized with BamHI restriction
enzyme, and used as a template in 20–25 cycles of PCR
amplification. After PCR amplification, DNA fragments
below 100 bp were removed using Agencourt AMPure
XP beads (Beckman Coulter). The amplified fragments
were sequenced by high-throughput sequencing on a
HiSeq 1500 (Illumina) to obtain 50-bp single reads. The
3′ linker, reverse transcription primers, and PCR primers
for amplification were as described previously [44].
Mapping of iCLIP reads
FASTQ reads were first demultiplexed according to the
barcode sequence RRRIIIIRR, in which R is a random
nucleotide and I is a part of the identifier sequence. The
two random segments were then stitched together into a
5-bp random tag used for identifying PCR duplicates
and saved within the read name. Following demulti-
plexing, the reads were quality trimmed and adapter
trimmed such that any adapter sequence at the 3′ end of
the reads was removed, allowing up to one mismatch.
Reads with a length of 20 bp or more were retained. For
these steps, we used custom Perl scripts. Next, reads
were mapped to the human genome (hg19) using the
Burrows-Wheeler Aligner (BWA) [83] (bwa aln parame-
ters: -l 20 -n 2, bwa samse parameters: -n 10) and, using
mapping positions together with the random tags, PCR
duplicates were removed using a custom Perl script. Tags
with up to one mismatch between them were considered
identical. This method allows detection of PCR duplicates
that contain sequencing errors, either in the random tag
or within the fragment sequence. Finally, we removed
non-uniquely aligned reads prior to downstream analyses.
iCLIP peak identification and motif analysis
Crosslinking sites were defined as the base immediately
preceding the read start for reads without deletions, while
the crosslinking site in reads containing deletions was de-
fined as the site of the deletion. The mapping of crosslink-
ing sites to the beginning of fragments was validated using
iCLIPro [51] to estimate the overall crosslinking profile of
hnRNP A1 in our iCLIP experiments. The program was
run on aligned fragments of lengths 20–35 bp compared to
fragments of length 41 bp in windows of 300 bp containing
at least 20 aligned fragments. To identify binding sites, we
extended these crosslinking sites by 10 bp to either side, or
in reads with deletions it was defined as ±10 bases from the
deletion site. Peak detection was performed on these re-
gions using CLIPper [84]. We used the “superlocal” algo-
rithm to account for local sequencing bias in 1-kb flanking
regions, and the “random” algorithm to estimate p values
within these windows. We set a threshold at FDR = 10 % to
identify significant binding sites with full parameters: -s
hg19 –premRNA –disable_global_cutoff –FDR = 0.1
–superlocal –threshold-method = random. To identify
binding motifs, we used the HOMER analysis program
[85] run in RNA mode on the identified binding sites with
the exact sizes of the binding sites as the targets, and a
random similarly sized set of regions as the background
(full parameters: -rna -size given -len 6,7,8 -mis 3 -depth
high –basic). To generate the scoring matrix we used the
frequency matrix to compute log2 scores of the frequen-
cies relative to a background frequency of 0.25. We down-
loaded raw fastq files for the hnRNP A1 samples from the
study of Huelga et al. [17] and mapped them with BWA
as described for our own data. We removed PCR dupli-
cates based on mapping position and then removed non-
uniquely aligned reads. To identify binding sites, we
performed peak detection using CLIPper directly on the
mapped reads. We used BEDTools to identify overlapping
binding sites. FDR values were calculated by adjusting
p values using the Benjamini-Hochberg method.
Genomic distribution of binding peaks
We used the RSeQC [86] package to calculate genomic
distributions and ngs.plot [87] to plot them in localized
windows. Overall densities across genomic regions
(Ensembl version 75) were calculated by normalizing to
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the total combined length of the region in question
(reads per kb), while plotted densities were normalized
to the total number of reads (reads per million). The
alignment of iCLIP reads to the human genome was
visualized using the Integrative Genomics Viewer (IGV)
[88, 89]. Coverage profiles of iCLIP tags and peaks were
created using ngs.plot [90].
RNA affinity purification
RNA affinity purification was performed as previously
described [8]. For each purification 100 pmol of RNA oli-
gonucleotides (Additional file 16: Materials and methods)
was coupled to 50 μl of streptavidin-coupled magnetic
beads (Life) and incubated with HeLa nuclear extract
(CilBiotech s.a.). After washing, bound proteins were
investigated by western blotting. The experiments were
performed two or three independent times.
Knockdown of hnRNP A1
HeLa cells were cultured in RPMI 1640 with L-glutam-
ine (Lonza) supplemented with streptomycin, penicillin,
and glutamine. Cells were seeded in 6-well plates and
transfected in duplicate with siRNA smartpool targeting
hnRNP A1 (L-008221-00) or non-targeting siRNA
(D-001810-10-20) (both from Dharmacon) using Lipo-
fectamine RNAiMAX (Life Technologies) following the
manufacturer’s instructions. After 24 h, the cells were
transfected again with siRNAs using Lipofectamine RNAi-
MAX and the forward transfection protocol. After 96 h in
total, the cells were harvested for RNA and protein ana-
lysis. Knockdown was performed three independent times.
RNA was isolated using Isol-RNA Lysis Reagent (5 Prime).
The RNA was treated with RQ1 RNase-Free DNase
(Promega) and 1 μg of RNA was reverse-transcribed using
the High-Capacity Reverse Transcription Kit (Life
Technologies). cDNA was used for qPCR using FastStart
Essential DNA Green Master (Roche) and the LightCycler
480 instrument II (Roche), or PCR using TEMPase
Hotstart Mastermix (Ampliqon), and analyzed by agarose
gel electrophoresis (using an Advanced Analytical Tech-
nologies system). Agarose gels were semi-quantified using
the ImageJ software package [91]. Primer sequences can
be found in Additional file 16: Materials and methods.
Western blotting
Protein was extracted using M-PER Mammalian Protein
Extraction Reagent (Thermo Scientific). Proteins were
separated on a 4–12 % Bis-Tris gel using the NuPAGE
SDS Gel System (Life Technologies) and membranes
were probed with anti-T7-tag antibody (AK42, Cold
Spring Harbor Laboratory), anti-hnRNP A1 (R9778,
Sigma-Aldrich), anti-hnRNP H (sc-10042, Santa Cruz
Biotechnology), anti-TDP-43 (10782-2-AP, Proteintech
Group), or anti-HPRT (HPA006360, Sigma-Aldrich).
RNA sequencing
Three biological replicates of hnRNP A1 knockdown in
HeLa cells were prepared for RNA sequencing using the
TruSeq Stranded Total RNA library Prep Kit, Human/
mouse/rat (Illumina). Samples were paired-end sequenced
using Illumina’s HiSeq 1500. Reads were subsequently
mapped with Spliced Transcripts Alignment to a
Reference (STAR) [92], and gene expression analysis was
carried out using HTSeq [93] and DESeq2 [94] with con-
ditional quantile normalization [95]. We used SAJR [96]
to detect alternative splicing and select significant events as
those with FDR <0.1. FDR values for all analyses were cal-
culated by adjusting p values using the Benjamini-
Hochberg method. To compare significant splicing changes
of cassette exons, we extracted cassette exons that
overlapped the intronic regions with cassette exon mis-
splicing indicated in the Huelga et al. data made public at
http://rnabind.ucsd.edu and with identical cassette exon
lengths. Log2 fold-change estimates from SAJR analysis
were computed by taking the log2 of the ratio between
conditions of the average inclusion ratios with 1 % pseu-
doinclusion added to each condition.
Transfection of splice-switching oligonucleotides
A549, HEK293, or HeLa cells were cultured in RPMI 1640
with L-glutamine (Lonza) supplemented with strepto-
mycin, penicillin, and glutamine. Cells were reverse-
transfected in duplicate using Lipofectamine RNAiMAX
(Life Technologies) following the manufacturer’s instruc-
tions using either 40 nM splice-switching oligonucleotides
(SSOs) or, for the dose-response curve, 1–16 nM. The
2′-OMe phosphorothioate SSOs (Additional file 16:
Materials and methods) were synthesized by DNA
Technology. The cells were harvested 48 h after trans-
fection, and RNA was isolated using Isol-RNA Lysis
Reagent (5 Prime) and reverse-transcribed using the High-
Capacity Reverse Transcription Kit (Life Technologies).
PCR was performed using TEMPase Hotstart Mastermix
(Ampliqon) and analyzed by agarose gel electrophoresis.
Bands were quantified using either ImageJ [91] or the
Fragment Analyzer (Advanced Analytical Technologies).
SKA2 minigenes
A fragment of the human SKA2 gene encompassing
exon 2, the first 200 bp of intron 2, an XhoI cleavage
site, the last 1105 bp of intron 2, exon 3, the first
1000 bp of intron 3, a BamHI cleavage site, the last
200 bp of intron 3, and the first 200 bp of exon 4 was
cloned into pcDNA3.1+ (GenScript). The mutant mini-
gene (Mut) contains A > C substitutions at five potential
hnRNP A1 binding sites adjacent to the exon 3 5′ splice
site. Minigenes were transfected in duplicate into HeLa
cells with X-tremeGENE 9 (Roche) according to the
manufacturer’s instructions.
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Additional files
Additional file 1: Figure S1. hnRNP A1 iCLIP. A. The inducible
expression of T7-hnRNP A1 analyzed by western blotting using either
anti-hnRNP A1 antibody or anti-T7 antibody. B. iCLIP was performed three
independent times. Autoradiography from one representative iCLIP is
shown. Western blotting of input samples confirms antibody-specific
immunoprecipitation of hnRNP A1. C. Scoring matrix based on the
frequencies of bases in the hnRNP A1 binding motif (Fig. 1). (TIF 1098 kb)
Additional file 2: Table S1. iCLIP raw reads and alignment. Table S2.
hnRNP A1-regulated cassette exons in disease-associated genes. Table S3.
Comparison with Huelga et al. hnRNP A1 HITS-CLIP. Table S4. Comparison
with Huelga et al. hnRNP A1 knockdown. (DOCX 52 kb)
Additional file 3: Figure S2. High-resolution read overlap heat map of
hnRNP A1 iCLIP reads. Density of read start (top), center (middle), and
end (bottom) indicated by colors and according to read length (y-axis)
(20–35 nt) compared to reads of 41 bases (group R). The distributions are
normalized to the total number of reads of that length. The hnRNP A1
iCLIP reads cluster around the read start sites, indicating that the hnRNP
A1 crosslinking sites are located close to the read start site. (TIF 4883 kb)
Additional file 4: Lists of hnRNP A1 iCLIP binding peaks, hnRNP A1
iCLIP binding peaks in cassette exons including 50 bp in flanking introns,
and gene expression and exon usage changes after hnRNP A1 knockdown
in HeLa cells (FDR <0.1). In addition, a list of the genes with hnRNP A1
binding peaks in cassette exons including 50 bp in flanking introns present
in the Orphanet, ClinVar (Pathogenic LoF), or Developmental Disorders
(DDG2P) databases (NCBI). The complete output from the RNA
sequencing and iCLIP analysis can be found in the ArrayExpress
database (https://www.ebi.ac.uk/arrayexpress/) under accession
number E-MTAB-3612. (XLSX 2197 kb)
Additional file 5: Figure S3. hnRNP A1-repressed exons have lower GC
content than unaffected exons. The GC content in the 3′ splice site (3′ss),
5′ splice site (5′ss), and exon region of exons activated or repressed by
hnRNP A1 or neutral exons is shown. *p value < 0.05. ns non-significant.
Error bars are standard error of mean. (TIF 2004 kb)
Additional file 6: Figure S4. hnRNP A1 iCLIP identifies well-known
hnRNP A1 binding sites in PKM and the N1 silencer of SMN1/SMN2.
A. hnRNP A1 iCLIP reads in PKM exons 9 and 10. hnRNP A1 reads are
depicted as horizontal gray bars. The read density is depicted as vertical
gray bars, and significant binding peaks are marked with blue bars. The
gene is on the antisense strand. An hnRNP A1 binding peak across the
reported splicing silencer (ESS) in PKM exon 10 (red bar). B. Non-uniquely
aligned reads (open bars) located at the N1 hnRNP A1-dependent silencer
(N1 ISS) in SMN1/SMN2 intron 7. (TIF 2535 kb)
Additional file 7: Figure S5. hnRNP A1 binds BRCA1 exon 11 and
BRCA2 exon 11 and SNPs disrupt hnRNP A1 binding. A. IGV screenshot of
the distribution of hnRNP A1 iCLIP reads in BRCA1. B. The same in BRCA2.
hnRNP A1 iCLIP reads are enriched in the long exons 11. C. RNA-affinity
chromatography of biotin-conjugated RNA oligonucleotides carrying
wild-type or SNP-containing BRCA1 or BRCA2 sequences, and subsequent
western blotting with hnRNP A1 or as control TDP43 antibody. The
sequences of the biotin-conjugated RNA oligonucleotides are listed.
hnRNP A1 motifs are underscored, and the SNP variant disrupting the
hnRNP A1 binding motif is red. (TIF 2004 kb)
Additional file 8: Figure S6. hnRNP A1 binds downstream of the
pseudoexon in SKA2 exon 3. A. Western blot of proteins purified by
RNA-affinity chromatography of biotin-conjugated RNA oligonucleotides
covering all the putative hnRNP A1 binding sites near the 5′ splice site of
SKA2 exon 3. hnRNP A1 binding motifs are underscored, and mutations
disrupting the hnRNP A1 binding motifs are shown in red. Introduction of the
mutations reduces hnRNP A1 binding. Representative of two experiments.
B. Surface plasmon resonance imaging (SPRi) using RNA oligonucleotides
containing the SKA2 sequence downstream of the 5′ splice site or mutant
sequence (MUT) where the hnRNP A1 binding motifs were mutated (Fig. 4).
RNA oligonucleotides were immobilized in array format on a hydrogel-coated
gold surface. Binding of hnRNP A1 was measured in real time by following
changes of the SPR angles at all printed positions of the array during 3-min
injections of hnRNP A1 protein over the entire surface. Five injections of a
twofold titration series from 6.25–100 nM hnRNP A1 were injected in
sequence from the lowest concentration to the highest. A continuous flow
of SPR buffer (10 mM HEPES/KOH pH 7.9, 150 mM KCl, 10 mM MgCl2,
0.5 mM DTT) flowed over the surface before, between, and after the hnRNP
A1 injections to measure baseline and dissociation kinetics. Responses for a
calibration curve were created after the concentration series by measuring
SPR responses from defined dilutions of glycerol in running buffer (ranging
from 5–0 % glycerol) and of pure water as defined by the automated
calibration routine of IBIS MX-96. Left: Increasing concentrations
of recombinant hnRNP A1 were injected over the surface to monitor
concentration-dependent association. Right: Binding of hnRNP A1 at
equilibrium. No binding was observed to the SKA2 MUT oligonucleotides,
suggesting that hnRNP A1 binds in a sequence-dependent way. ka, kd:
kinetic association and dissociation rate constants, KD: (kd/ka): equilibrium
dissociation constant calculated from the ratio kd/ka, KD (eq.): equilibrium
dissociation constant calculated from steady-state binding responses, +/-:
average and +/- standard deviation of n = 1. (TIF 1425 kb)
Additional file 9: Figure S7. SKA2 minigene. A. SKA2 minigenes
containing the wild-type sequence or mutated hnRNP A1 binding sites
downstream of the exon 3 5′ splice site were transfected into HeLa cells.
B. Inclusion levels were quantified using the fragment analyzer. PSI
percent spliced in. n = 2. C. SKA2 SSO transfections improve splicing of the
SKA2 exon 3 wild-type minigene. Quantified using the fragment analyzer.
PSI percent spliced in. n = 2. D. Increasing concentrations of SKA2 SSO
improves SKA2 exon 3 inclusion. Inclusion ratios were quantified using the
fragment analyzer. For comparison the effect of 40 nM SSO is shown (as in
Fig. 4). (TIF 1295 kb)
Additional file 10: Figure S8. Mutations in the hnRNP A1 binding
motifs downstream of the MTRR pseudoexon reduce hnRNP A1 binding
affinity. The first UAG motif is responsible for hnRNP A1 binding. Surface
plasmon resonance imaging using RNA oligonucleotides containing the
MTRR wild-type or mutant sequences downstream of the 5′ splice site.
Left: Increasing concentrations of recombinant hnRNP A1 were injected
over the surface to monitor concentration-dependent association. Right:
Binding of hnRNP A1 at equilibrium. No binding was observed to the
MTRR MUT C and MUT D oligonucleotides, suggesting that the proximal
UAG motif is necessary for hnRNP A1 binding. ka, kd: kinetic association
and dissociation rate constants, KD: (kd/ka): equilibrium dissociation
constant calculated from the ratio kd/ka, KD (eq.): equilibrium dissociation
constant calculated from steady-state binding responses, +/-: average
and +/- standard deviation of n = 2–-4. (TIF 3125 kb)
Additional file 11: Figure S9. hnRNP A1 binds downstream of the
pseudoexon in COL4A5. A. Western blot with hnRNP A1 or as control
hnRNP H antibody of proteins purified by RNA-affinity chromatography
of biotin-conjugated RNA oligonucleotides covering the downstream
region of the COL4A5 pseudoexon 5′ splice site. Disruption of the hnRNP
A1 binding motif reduces hnRNP A1 binding. The motifs are scored using
our generated scoring matrix (Additional file 1: Figure S1). Representative
of two experiments. B. Surface plasmon resonance imaging using RNA
oligonucleotides containing the COL4A5 sequence downstream of the 5′
splice site or mutant sequences (MUT) where the hnRNP A1 binding
motifs were mutated. Left: Increasing concentrations of recombinant hnRNP
A1 were injected over the surface to monitor concentration-dependent
association. Right: Binding of hnRNP A1 at equilibrium. No binding was
observed to the COL4A5 MUT oligonucleotides, suggesting that hnRNP A1
binds here in a sequence-dependent way. ka, kd: kinetic association and
dissociation rate constants, KD: (kd/ka): equilibrium dissociation constant
calculated from the ratio kd/ka, KD (eq.): equilibrium dissociation constant
calculated from steady-state binding responses, +/-: average and +/- standard
deviation of n = 2. (TIF 1448 kb)
Additional file 12: Figure S10. hnRNP A1 binding peak near the
COL4A5 pseudoexon. A. RT-PCR analysis shows that knockdown of hnRNP
A1 does not increase COL4A5 pseudoexon inclusion. B. hnRNP A1 binding
peak (blue bar) near the 5′ splice site of the COL4A5 pseudoexon. The SSO
binding site is shown. C. COL4A5 SSO transfections in HeLa and HEK293
cells decrease pseudoexon inclusion. (TIF 1448 kb)
Additional file 13: Figure S11. Increasing the concentration of the
MTRR SSO improves MTRR pseudoexon inclusion. Transfection of
increasing concentrations of MTRR SSO into HeLa cells improves MTRR
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pseudoexon inclusion. Quantification of the MTRR pseudoexon inclusion
level after MTRR SSO treatment was based on data from the fragment
analyzer. For comparison, the effect of 40 nM SSO is shown (same as Fig. 5).
(TIF 672 kb)
Additional file 14: Figure S12. Increased affinity of hnRNP A1 to the
ETFDH mutant RNA oligonucleotide. Surface plasmon resonance imaging:
RNA oligonucleotides containing the ETFDH wild-type or mutant
sequences where the important UAG is mutated to UCG were immobilized
in array format on a hydrogel-coated gold surface. Left: Increasing
concentrations of hnRNP A1 were injected over the surface to monitor
concentration-dependent association. Right: Binding of hnRNP A1 at
equilibrium. ka, kd: kinetic association and dissociation rate constants,
KD: (kd/ka): equilibrium dissociation constant calculated from the ratio
kd/ka, KD (eq.): equilibrium dissociation constant calculated from steady-state
binding responses, +/-: average and +/- standard deviation of n = 4.
(TIF 1621 kb)
Additional file 15: Figure S13. hnRNP A1 binds to hnRNP A2/B1 and
hnRNP A1. hnRNP A1 iCLIP binding peaks were abundant in the pre-mRNAs
encoding hnRNP proteins, in particular in the 3′ UTR region. A. hnRNP A1
iCLIP reads across the HNRNP A2/B1 gene. B. hnRNP A1 iCLIP reads around
the alternative exon 7B in HNRNP A1. (TIF 3350 kb)
Additional file 16: Materials and methods. Lists of RNA oligonucleotide
sequences, splice-switching oligonucleotide sequences, and primer
sequences. Description of the surface plasmon resonance imaging.
(DOCX 22 kb)
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